Drug Discovery

All articles

Genotoxic method development

One pager4 min read

Genotoxic method development Read more

Making sense of phase appropriate analytical methods

Making Sense of4 min read

Making sense of phase appropriate analytical methods Read more

Overcoming elemental impurities scenario sheet

One pager5 min read

Overcoming elemental impurities Read more

Making sense of solid state chemistry preview

Making Sense of2 min read

Making sense of solid state chemistry Read more

Making sense of early phase research and development

Making Sense of1 min read

Making sense of early phase research and development Read more

One pager2 min read

Total antibody quantification of an ADC after plasma incubation

A key feature of monoclonal antibody (mAb) proteins is their stability in plasma due to their resistance to proteases.

Read more

AN-009 reduced subunit analysis of a PDB based antibody drug conjugate

One pager2 min read

Reduced subunit analysis of a PDB based antibody drug conjugate

Subunit analysis of Zynlonta using a SCIEX X500B Mass Spectrometer

Read more

Picture of Chris Nortcliffe, Mass Spectrometry Manager at Sterling, presenter of "The use of mass spectrometry to aid ADC development" webinar

Webinar13 min read

The use of mass spectrometry to aid ADC development Read more

One pager3 min read

Measurement of ADC free drug after plasma incubation

Antibody drug conjugates (ADCs) combine a monoclonal antibody (mAb) scaffold with a number of cytotoxic drugs.

Read more

Next Page »

Explore more

All ADCs API Development API Manufacturing Analytical Services Drug Discovery Facilities News PDMO People Peptides Sustainability Technologies

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

X/Twitter

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229